Shares of TESARO Inc (NASDAQ:TSRO) have received an average rating of “Buy” from the twenty-one ratings firms that are covering the firm. Eight investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $170.71.
TSRO has been the subject of several research reports. Bank of America Corp upped their target price on TESARO from $149.26 to $165.00 in a research note on Thursday, January 19th. SunTrust Banks, Inc. reissued an “average” rating and set a $190.00 price objective on shares of TESARO in a research note on Thursday, February 9th. They noted that the move was a valuation call. FBR & Co reissued a “buy” rating on shares of TESARO in a research note on Thursday, January 12th. Credit Suisse Group AG set a $151.00 price objective on TESARO and gave the company a “buy” rating in a research note on Thursday, January 12th. Finally, Citigroup Inc increased their price objective on TESARO from $151.00 to $232.00 and gave the company a “buy” rating in a research note on Thursday, February 9th.
ILLEGAL ACTIVITY NOTICE: “Analysts Set TESARO Inc (TSRO) Price Target at $174.16” was first reported by BBNS and is the property of of BBNS. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/tesaro-inc-tsro-receives-174-16-average-price-target-from-analysts-updated/580621.html.
Shares of TESARO (NASDAQ:TSRO) traded down 2.1609% on Friday, reaching $136.0061. 701,120 shares of the company traded hands. TESARO has a 52-week low of $36.68 and a 52-week high of $192.94. The stock has a 50 day moving average of $155.40 and a 200 day moving average of $144.38. The stock’s market cap is $7.29 billion.
In other TESARO news, VP Edward C. English sold 229 shares of the stock in a transaction on Thursday, March 2nd. The stock was sold at an average price of $177.61, for a total value of $40,672.69. Following the completion of the transaction, the vice president now owns 625 shares in the company, valued at $111,006.25. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $153.02, for a total value of $126,853.58. Following the completion of the transaction, the senior vice president now owns 6,522 shares of the company’s stock, valued at approximately $997,996.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,432 shares of company stock valued at $2,902,602. 40.50% of the stock is owned by corporate insiders.
Several institutional investors have recently modified their holdings of TSRO. Macquarie Group Ltd. boosted its stake in shares of TESARO by 4.8% in the fourth quarter. Macquarie Group Ltd. now owns 301,510 shares of the biopharmaceutical company’s stock worth $40,547,000 after buying an additional 13,830 shares during the last quarter. Tocqueville Asset Management L.P. boosted its stake in shares of TESARO by 18.6% in the third quarter. Tocqueville Asset Management L.P. now owns 37,650 shares of the biopharmaceutical company’s stock worth $3,774,000 after buying an additional 5,900 shares during the last quarter. DIAM Co. Ltd. acquired a new stake in shares of TESARO during the third quarter worth $3,532,000. Airain ltd acquired a new stake in shares of TESARO during the third quarter worth $5,410,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of TESARO by 249.0% in the third quarter. Bank of New York Mellon Corp now owns 493,701 shares of the biopharmaceutical company’s stock worth $49,490,000 after buying an additional 352,228 shares during the last quarter. Hedge funds and other institutional investors own 98.48% of the company’s stock.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with our FREE daily email newsletter.